BIOHARVEST SCIENCES INC - CNVCF STOCK NEWS

Welcome to our dedicated page for BIOHARVEST SCIENCES news (Ticker: CNVCF), a resource for investors and traders seeking the latest updates and insights on BIOHARVEST SCIENCES stock.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a pioneering biotechnology company with a focus on Botanical Synthesis. The company leverages its patented technology platform to produce plant-based molecules without the need to grow the underlying plant. BioHarvest is actively engaged in developing science-based and clinically proven therapeutic solutions in nutraceutical health and wellness products, including dietary supplements, and the creation of plant cell-based Active Pharmaceutical Ingredients (APIs) for specific medical indications. With a strong emphasis on innovation and research, BioHarvest aims to revolutionize the health and wellness industry with its cutting-edge products.

05/01/2024 09:15 AM

News

BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 P.M. Eastern Time

Rhea-AI Summary

BioHarvest Sciences Inc. will host a corporate update call on May 2nd to discuss milestone achievements, including full year 2023 financial results and the recent acquisition of an expanded corporate campus. The call will feature CEO Ilan Sobel and Chairman Zaki Rakib, providing comments on financial results, the corporate campus acquisition, and the path towards Nasdaq listing requirements.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.47%

Tags

04/30/2024 08:00 AM

News

BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

BioHarvest Sciences reported a significant revenue increase in FY 2023, with revenue growing 131% to $12.7 million. The company expects Q1 2024 revenue between $5.2-$5.3 million and Q2 2024 revenue between $5.7-$6.0 million. BioHarvest is pursuing a Nasdaq listing by year-end and has called a meeting to approve share consolidation and add an independent director. Operational highlights include improved gross margins, new product launches, and the establishment of a Contract Development and Manufacturing Organization (CDMO) business unit. The company is focused on margin optimization and achieving EBITDA profitability in the second half of 2024. BioHarvest's strategic goals align with their commitment to a Nasdaq uplisting and enhancing shareholder value.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.05%

Tags

04/16/2024 08:00 AM

News

BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity

Rhea-AI Summary

BioHarvest Sciences announces the establishment of a new campus for Botanical Synthesis CDMO and the expansion of manufacturing capacity. The 80,000 square foot property in Yavne, Israel, includes 12 GMP clean rooms, laboratory and office space, and can accommodate a new 50-ton manufacturing facility. The company signed agreements for equipment purchase and a long-term lease, investing in state-of-the-art clean rooms and laboratory spaces. The new facility is expected to house all R&D functions and a new manufacturing facility in 2025, with upgraded equipment and technologies to improve production yields and efficiencies. CEO Ilan Sobel expresses excitement about consolidating corporate, R&D, and production footprints under one roof to support the growth of CDMO services and products business.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.74%

Tags

03/21/2024 08:30 AM

News

BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables

Rhea-AI Summary

BioHarvest Sciences Inc. appoints experienced life sciences executive Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables, to drive growth in their Contract Development and Manufacturing Organization (CDMO) Services Business Unit. Tenstam's extensive experience in pharmaceutical, cosmeceutical, and nutraceutical industries positions BioHarvest to attract development and manufacturing contracts, creating sustainable long-term value for shareholders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.09%

Tags

03/14/2024 08:30 AM

News

BioHarvest Sciences to Participate in Benzinga Virtual Healthcare Summit 2024 on March 20, 2024

Rhea-AI Summary

BioHarvest Sciences Inc. to Participate in Benzinga Virtual Healthcare Summit 2024, CEO Ilan Sobel to Discuss Recent Milestones

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

13.77%

Tags

03/13/2024 09:21 AM

News

BioHarvest Sciences Announces New Strategic Hires for CDMO Services Business Unit

Rhea-AI Summary

BioHarvest Sciences Inc. appoints key leadership roles in business development and science for its newly launched CDMO Services Business Unit. Matt Zrebiec joins as VP of Business Development, bringing 23 years of experience in the pharmaceutical sector. Professor Itay Mayrose is appointed as a Senior AI Scientist, known for his expertise in plant computational genomics. The company aims to leverage AI algorithms for molecule development and expand into pharma, cosmetics, and nutrition industries.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.45%

Tags

03/07/2024 08:30 AM

News

BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on March 12-13, 2024

Rhea-AI Summary

BioHarvest Sciences Inc. (CNVCF) to present at iAccess Alpha Buyside Best Ideas Investor Conference, CEO to host virtual meetings with institutional investors. Event details and registration information provided.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.19%

Tags

02/29/2024 11:15 AM

News

BioHarvest Sciences to Host Corporate Update Discussing Launch of CDMO Business Unit on March 13 at 2:30 p.m. Eastern Time

Rhea-AI Summary

BioHarvest Sciences Inc. announces the launch of a Contract Development and Manufacturing Organization (CDMO) business unit, offering pharmaceutical, cosmeceutical, nutraceutical, and nutrition industry leaders access to its Botanical Synthesis Process technology. The new unit aims to provide unique advantages such as lower costs, faster development speed, manufacturing consistency, and enhanced safety. CEO Ilan Sobel and Chairman Zaki Rakib will host a webinar to discuss the CDMO business unit, corporate updates, and future plans.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.42%

Tags

02/26/2024 08:30 AM

News

BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules via Its Newly Launched Botanical Synthesis CDMO Business Unit

Rhea-AI Summary

BioHarvest Sciences Inc. launches a new Contract Development and Manufacturing Organization (CDMO) business unit, signing contracts with a NASDAQ-listed pharmaceutical company and a major player in the nutrition and ingredients industry. The CDMO offers the Botanical Synthesis process technology for developing complex molecules, known as BIOLOGICS+, with advantages like lower costs, faster development, and safety enhancements. The process involves 3 major steps with associated costs and timelines. The company aims to address unmet needs in various industries and has potential royalty-based payment models for industrial manufacturing.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.03%

Tags

02/20/2024 02:16 PM

News

BioHarvest Sciences Issues Clarification to February 15, 2024 News Release Announcing Engagement with IR Firm

Rhea-AI Summary

BioHarvest Sciences Inc. clarifies engagement with MZ Group and provides additional information on revenue estimates and market potential. The company aims for 125% year-over-year revenue growth, $12.4 million in revenue, and profitability by the third quarter of 2024. The Health and Wellness Industry's estimated value is $1.5 trillion with a 5 to 10% annual growth rate. BioHarvest focuses on nutraceutical and functional food markets, valued at $317.2 billion and $280.7 billion respectively.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of BIOHARVEST SCIENCES (CNVCF)?

The current stock price of BIOHARVEST SCIENCES (CNVCF) is $5.99 as of October 14, 2024.

What is the market cap of BIOHARVEST SCIENCES (CNVCF)?

The market cap of BIOHARVEST SCIENCES (CNVCF) is approximately 109.9M.

What is the core business of BioHarvest Sciences Inc.?

BioHarvest Sciences Inc. focuses on Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules.

What are the main products of BioHarvest Sciences Inc.?

The company specializes in nutraceutical health and wellness products, including dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs).

What is BioHarvest Sciences Inc.'s approach to therapeutic solutions?

BioHarvest Sciences Inc. is committed to developing science-based and clinically proven therapeutic solutions using innovative botanical synthesis technology.

What are some recent achievements of BioHarvest Sciences Inc.?

Recent achievements include strong revenue growth, margin optimization, the launch of a Contract Development and Manufacturing Organization (CDMO) Services Business Unit, and signing contracts with notable pharmaceutical and food nutrition industry players.

What are BioHarvest Sciences Inc.'s future growth plans?

BioHarvest Sciences Inc. aims to achieve EBITDA break even in the second half of 2024, secure an uplisting to the Nasdaq Stock Market, and continue delivering shareholder value through product innovation and business expansion.